Furiex Pharmaceuticals, Inc. (FURX)
-NasdaqGS | Prev Close: | 44.61 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 55.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 17.50 - 49.50 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 58,895 |
|---|
| Market Cap: | 459.35M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Furiex Pharmaceuticals enters into a loan agreement for $15 mln and restructures its existing secured loanBriefing.com(Tue, Oct 1)
- Furiex Pharmaceuticals Enters into a Loan Agreement for $15 Million and Restructures Its Existing Secured LoanBusiness Wire(Tue, Oct 1)
- EU Nod for Furiex Diabetes DrugsZacks(Wed, Sep 25)
- Furiex Confirms Takeda Receives European Marketing Authorization for VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone)Business Wire(Tue, Sep 24)
- Furiex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary EndpointBusiness Wire(Tue, Sep 3)
- FURIEX PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Thu, Aug 15)
- Investors Are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Mon, Aug 12)
- FURIEX PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Aug 8)
- Furiex Pharmaceuticals Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Aug 7)
- FURIEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Tue, Aug 6)
- Furiex Reports Second Quarter 2013 Financial ResultsBusiness Wire(Tue, Aug 6)
- Q2 2013 Furiex Pharmaceuticals Inc Earnings Release - After Market CloseCCBN(Tue, Aug 6)
- The Best- And Worst-Performing Biotech Stocks July 19 To July 26at Forbes(Sun, Jul 28)
- Furiex Confirms Takeda Receives Positive CHMP Opinion for VIPIDIA™ (alogliptin) and Fixed-Dose Combinations VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone)Business Wire(Fri, Jul 26)
- 4 Unusual-Volume Stocks to Watchat TheStreet(Thu, Jul 25)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.85 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -3.39 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -1.83 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -0.10 |
|---|
Business Summary
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by ...
View More
0.41%